TALIS BIOMEDICAL CORP (TLIS) Fundamental Analysis & Valuation

NASDAQ:TLIS • US87424L2079

Current stock price

4.38 USD
+0.22 (+5.29%)
At close:
4.49 USD
+0.11 (+2.51%)
After Hours:

This TLIS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. TLIS Profitability Analysis

1.1 Basic Checks

  • TLIS had negative earnings in the past year.
  • TLIS had a negative operating cash flow in the past year.
  • In the past 5 years TLIS reported 4 times negative net income.
  • TLIS had a negative operating cash flow in each of the past 5 years.
TLIS Yearly Net Income VS EBIT VS OCF VS FCFTLIS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

  • With a Return On Assets value of -69.35%, TLIS is not doing good in the industry: 77.78% of the companies in the same industry are doing better.
  • Looking at the Return On Equity, with a value of -100.93%, TLIS is doing worse than 67.20% of the companies in the same industry.
Industry RankSector Rank
ROA -69.35%
ROE -100.93%
ROIC N/A
ROA(3y)-68.16%
ROA(5y)-29.58%
ROE(3y)-86.99%
ROE(5y)-37.77%
ROIC(3y)N/A
ROIC(5y)N/A
TLIS Yearly ROA, ROE, ROICTLIS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 100 -100 -200

1.3 Margins

  • Looking at the Gross Margin, with a value of 97.27%, TLIS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • The Profit Margin and Operating Margin are not available for TLIS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TLIS Yearly Profit, Operating, Gross MarginsTLIS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -1K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. TLIS Health Analysis

2.1 Basic Checks

  • TLIS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TLIS has more shares outstanding than it did 1 year ago.
  • TLIS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TLIS Yearly Shares OutstandingTLIS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 500K 1M 1.5M
TLIS Yearly Total Debt VS Total AssetsTLIS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

  • TLIS has an Altman-Z score of -10.46. This is a bad value and indicates that TLIS is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of TLIS (-10.46) is worse than 82.01% of its industry peers.
  • TLIS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.46
ROIC/WACCN/A
WACC8.69%
TLIS Yearly LT Debt VS Equity VS FCFTLIS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 7.51 indicates that TLIS has no problem at all paying its short term obligations.
  • TLIS's Current ratio of 7.51 is amongst the best of the industry. TLIS outperforms 84.66% of its industry peers.
  • A Quick Ratio of 7.51 indicates that TLIS has no problem at all paying its short term obligations.
  • TLIS has a better Quick ratio (7.51) than 88.36% of its industry peers.
Industry RankSector Rank
Current Ratio 7.51
Quick Ratio 7.51
TLIS Yearly Current Assets VS Current LiabilitesTLIS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. TLIS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 42.72% over the past year.
  • Looking at the last year, TLIS shows a very negative growth in Revenue. The Revenue has decreased by -65.21% in the last year.
  • Measured over the past years, TLIS shows a decrease in Revenue. The Revenue has been decreasing by -2.24% on average per year.
EPS 1Y (TTM)42.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.28%
Revenue 1Y (TTM)-65.21%
Revenue growth 3Y-42%
Revenue growth 5Y-2.24%
Sales Q2Q%-93.25%

3.2 Future

  • TLIS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.67% yearly.
  • TLIS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 154.95% yearly.
EPS Next Y27.62%
EPS Next 2Y6.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y154.95%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TLIS Yearly Revenue VS EstimatesTLIS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2025 2M 4M 6M 8M 10M
TLIS Yearly EPS VS EstimatesTLIS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -50 -100

More info and screens

Find the best growth stocksShow best growing peers

0

4. TLIS Valuation Analysis

4.1 Price/Earnings Ratio

  • TLIS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year TLIS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLIS Price Earnings VS Forward Price EarningsTLIS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TLIS Per share dataTLIS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.67%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TLIS Dividend Analysis

5.1 Amount

  • TLIS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

TLIS Fundamentals: All Metrics, Ratios and Statistics

TALIS BIOMEDICAL CORP

NASDAQ:TLIS (8/30/2024, 8:26:04 PM)

After market: 4.49 +0.11 (+2.51%)

4.38

+0.22 (+5.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Industry Strength9.94
Industry Growth61.49
Earnings (Last)08-07
Earnings (Next)11-12
Inst Owners21.86%
Inst Owner Change0%
Ins Owners18.29%
Ins Owner Change0%
Market Cap7.97M
Revenue(TTM)989.00K
Net Income(TTM)-57.21M
Analysts36.67
Price Target5.1 (16.44%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.06
P/FCF N/A
P/OCF N/A
P/B 0.14
P/tB 0.14
EV/EBITDA N/A
EPS(TTM)-31.43
EYN/A
EPS(NY)-28.34
Fwd EYN/A
FCF(TTM)-23.99
FCFYN/A
OCF(TTM)-23.74
OCFYN/A
SpS0.54
BVpS31.15
TBVpS31.15
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -69.35%
ROE -100.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.27%
FCFM N/A
ROA(3y)-68.16%
ROA(5y)-29.58%
ROE(3y)-86.99%
ROE(5y)-37.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 53.85%
Cap/Sales 46.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.51
Quick Ratio 7.51
Altman-Z -10.46
F-Score4
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)87.68%
Cap/Depr(5y)283.5%
Cap/Sales(3y)30.44%
Cap/Sales(5y)36.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.28%
EPS Next Y27.62%
EPS Next 2Y6.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-65.21%
Revenue growth 3Y-42%
Revenue growth 5Y-2.24%
Sales Q2Q%-93.25%
Revenue Next Year-100%
Revenue Next 2Y154.95%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y46.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.61%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y77.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.58%
OCF growth 3YN/A
OCF growth 5YN/A

TALIS BIOMEDICAL CORP / TLIS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for TALIS BIOMEDICAL CORP?

ChartMill assigns a fundamental rating of 3 / 10 to TLIS.


What is the valuation status of TALIS BIOMEDICAL CORP (TLIS) stock?

ChartMill assigns a valuation rating of 0 / 10 to TALIS BIOMEDICAL CORP (TLIS). This can be considered as Overvalued.


How profitable is TALIS BIOMEDICAL CORP (TLIS) stock?

TALIS BIOMEDICAL CORP (TLIS) has a profitability rating of 1 / 10.


Can you provide the financial health for TLIS stock?

The financial health rating of TALIS BIOMEDICAL CORP (TLIS) is 7 / 10.


What is the earnings growth outlook for TALIS BIOMEDICAL CORP?

The Earnings per Share (EPS) of TALIS BIOMEDICAL CORP (TLIS) is expected to grow by 27.62% in the next year.